HIV 感染中的 CCR5 拮抗作用：当前概念和未来机遇。
CCR5 antagonism in HIV infection: current concepts and future opportunities.
机构信息
Division of Infectious Diseases, Weill Medical College of Cornell University, New York, New York 10065, USA.
出版信息
Annu Rev Med. 2012;63:81-93. doi: 10.1146/annurev-med-052010-145454. Epub 2011 Oct 27.
Abstract
CCR5 antagonists inhibit HIV-1 entry by blocking the interaction of HIV-1 with the CCR5 cellular receptor. In patients with established HIV-1 infection, some viral strains use an alternative coreceptor for HIV-1 entry, CXCR4; CCR5 antagonists are not effective in patients harboring these viral strains. Coreceptor tropism testing of viral strains in an individual patient is necessary prior to treating with a CCR5 antagonist. There is one CCR5 antagonist, maraviroc, that is FDA-approved for treatment of HIV-1 infection. This drug is used most commonly for the treatment of HIV-1 infection in patients who have failed other antiretroviral regimens. In addition to virologic effects, CCR5 antagonists are under investigation for immune-modulating effects and for HIV-1 prevention. Ongoing research will further elucidate the role of CCR5 antagonists in combating HIV disease.
摘要
CCR5 拮抗剂通过阻止 HIV-1 与 CCR5 细胞受体的相互作用来抑制 HIV-1 的进入。在已感染 HIV-1 的患者中，一些病毒株使用 HIV-1 进入的替代共受体 CXCR4；对于携带这些病毒株的患者，CCR5 拮抗剂无效。在使用 CCR5 拮抗剂治疗之前，需要对个体患者的病毒株进行共受体嗜性测试。有一种 CCR5 拮抗剂，马拉维若，被 FDA 批准用于治疗 HIV-1 感染。这种药物最常用于治疗其他抗逆转录病毒方案失败的 HIV-1 感染患者。除了病毒学效果外，CCR5 拮抗剂还在研究其免疫调节作用和 HIV-1 预防作用。正在进行的研究将进一步阐明 CCR5 拮抗剂在对抗 HIV 疾病中的作用。
相似文献
1
CCR5 antagonism in HIV infection: current concepts and future opportunities.HIV 感染中的 CCR5 拮抗作用：当前概念和未来机遇。
Annu Rev Med. 2012;63:81-93. doi: 10.1146/annurev-med-052010-145454. Epub 2011 Oct 27.
2
Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.表征与R5嗜性马拉维若耐药相关的多种突变途径：利用药物结合型CCR5共受体的HIV-1
J Virol. 2015 Nov;89(22):11457-72. doi: 10.1128/JVI.01384-15. Epub 2015 Sep 2.
3
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.HIV-1亚型和嗜性对趋化因子共受体进入抑制剂治疗的影响；病毒进入抑制概述。
Crit Rev Microbiol. 2015;41(4):473-87. doi: 10.3109/1040841X.2013.867829. Epub 2014 Mar 17.
4
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.马拉维若：用于治疗 CCR5 嗜性 HIV-1 感染的综述。
Drugs. 2010 Jun 18;70(9):1189-213. doi: 10.2165/11203940-000000000-00000.
5
Clinical utility of maraviroc.马拉维若的临床应用。
Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000.
6
Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.马拉维若：一种用于治疗HIV感染的共受体CCR5拮抗剂。
Am J Health Syst Pharm. 2009 Apr 15;66(8):715-26. doi: 10.2146/ajhp080206.
7
Maraviroc: a review of its use in HIV infection and beyond.马拉维若：对其在HIV感染及其他方面应用的综述。
Drug Des Devel Ther. 2015 Oct 1;9:5447-68. doi: 10.2147/DDDT.S90580. eCollection 2015.
8
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.在少数接受CCR5拮抗剂马拉维若治疗的HIV-1感染患者中，出现利用CXCR4的1型人类免疫缺陷病毒（HIV-1）变体，这些变体来自治疗前利用CXCR4的病毒储存库。
J Virol. 2006 May;80(10):4909-20. doi: 10.1128/JVI.80.10.4909-4920.2006.
9
[Viral entry as therapeutic target. Current situation of entry inhibitors].[以病毒进入为治疗靶点。进入抑制剂的现状]
Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:5-11. doi: 10.1016/s0213-005x(08)76557-1.
10
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.评估 HIV-1 核心受体使用的基因型预测与表型测定的比较，以及与马拉维若治疗的病毒学反应的相关性：ANRS GenoTropism 研究。
Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7.
引用本文的文献
1
Mechanisms of Immune Evasion in HIV-1: The Role of Virus-Host Protein Interactions.HIV-1免疫逃逸机制：病毒-宿主蛋白相互作用的作用
Curr Issues Mol Biol. 2025 May 16;47(5):367. doi: 10.3390/cimb47050367.
2
Bid Protein: A Participant in the Apoptotic Network with Roles in Viral Infections.Bid蛋白：凋亡网络中的参与者及其在病毒感染中的作用
Int J Mol Sci. 2025 Mar 7;26(6):2385. doi: 10.3390/ijms26062385.
3
Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma.CCL3 的靶向递送可重编程巨噬细胞抗原呈递并增强免疫检查点阻断疗法在肝细胞癌中的疗效。
J Immunother Cancer. 2025 Feb 23;13(2):e010947. doi: 10.1136/jitc-2024-010947.
4
Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.当前的抗逆转录病毒疗法、病毒学失败及其对艾滋病管理的影响：系统评价。
Viruses. 2023 Aug 13;15(8):1732. doi: 10.3390/v15081732.
5
Comprehensive Network Analysis Reveals the Targets and Potential Multitarget Drugs of Type 2 Diabetes Mellitus.综合网络分析揭示 2 型糖尿病的作用靶点和潜在多靶药物。
Oxid Med Cell Longev. 2022 Jul 28;2022:8255550. doi: 10.1155/2022/8255550. eCollection 2022.
6
CCR5 closes the temporal window for memory linking.CCR5 关闭了记忆关联的时间窗口。
Nature. 2022 Jun;606(7912):146-152. doi: 10.1038/s41586-022-04783-1. Epub 2022 May 25.
7
Factors Affecting the Tissue Damaging Consequences of Viral Infections.影响病毒感染所致组织损伤后果的因素
Front Microbiol. 2019 Oct 4;10:2314. doi: 10.3389/fmicb.2019.02314. eCollection 2019.
8
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.含马拉维若的暴露前预防方案在男男性行为者中的药代动力学、药效学和黏膜反应。
AIDS. 2019 Feb 1;33(2):237-246. doi: 10.1097/QAD.0000000000002038.
9
Companion diagnostics: new opportunities for safe and effective anti-infectious disease therapies.伴随诊断：安全有效的抗传染病治疗的新机遇。
Emerg Microbes Infect. 2018 Jan 24;7(1):9. doi: 10.1038/s41426-017-0014-9.
10
Human genetics of infectious diseases: Unique insights into immunological redundancy.传染病的人类遗传学：对免疫冗余的独特见解。
Semin Immunol. 2018 Apr;36:1-12. doi: 10.1016/j.smim.2017.12.008. Epub 2017 Dec 16.
本文引用的文献
1
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.马拉维若与 CCR5 抗体 HGS004 协同抑制原发性细胞中的 R5 HIV-1：对治疗和预防的影响。
AIDS. 2011 Jun 1;25(9):1232-5. doi: 10.1097/QAD.0b013e3283471edb.
2
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.健康 HIV 阴性男性唾液、精液和直肠组织中马拉维若的单剂量和多剂量药代动力学。
J Infect Dis. 2011 May 15;203(10):1484-90. doi: 10.1093/infdis/jir059.
3
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.使用具有增强灵敏度的表型测定法重新分析感染 HIV-1 的成年人中的辅助受体嗜性。
Clin Infect Dis. 2011 Apr 1;52(7):925-8. doi: 10.1093/cid/cir072.
4
Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.TBR-652，一种 CCR5/CCR2 拮抗剂，在 HIV-1 感染、治疗经验丰富、CCR5 拮抗剂初治患者中的安全性、疗效和药代动力学。
J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. doi: 10.1097/QAI.0b013e318213c2c0.
5
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.CCR5拮抗剂与CD4+T细胞增加的关系：对有治疗经验的HIV感染患者近期临床试验的Meta回归分析
HIV Clin Trials. 2010 Nov-Dec;11(6):351-8. doi: 10.1310/hct1106-351.
6
CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.CCR5 抗体 HGS004 和 HGS101 优先抑制药物结合的 CCR5 感染，并恢复原发性细胞中马拉维若耐药 HIV-1 的药物敏感性。
Virology. 2011 Mar 1;411(1):32-40. doi: 10.1016/j.virol.2010.12.029. Epub 2011 Jan 12.
7
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.抗逆转录病毒药物拉替拉韦和马拉维若预防口腔暴露感染 HIV-1 阴道传播的效果：在人源化小鼠模型中的研究
PLoS One. 2010 Dec 21;5(12):e15257. doi: 10.1371/journal.pone.0015257.
8
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).一种用于治疗 HIV 的咪唑并哌啶系列 CCR5 拮抗剂：N-{(1S)-1-(3-氟苯基)-3-[(3-内)-3-(5-异丁酰基-2-甲基-4,5,6,7-四氢-1H-咪唑并[4,5-c]吡啶-1-基)-8-氮杂双环[3.2.1]辛-8-基]丙基}乙酰胺（PF-232798）的发现。
J Med Chem. 2011 Jan 13;54(1):67-77. doi: 10.1021/jm100978n. Epub 2010 Dec 3.
9
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.马拉维若和依非韦伦对免疫激活和炎症标志物的影响，以及与 HIV 感染患者 CD4+细胞升高的关联。
PLoS One. 2010 Oct 6;5(10):e13188. doi: 10.1371/journal.pone.0013188.
10
Hepatic safety and tolerability in the maraviroc clinical development program.马拉维若临床开发项目中的肝脏安全性和耐受性。
AIDS. 2010 Nov 13;24(17):2743-50. doi: 10.1097/QAD.0b013e32833f9ce2.
Zotero 插件